American Journal of Kidney Diseases
Volume 55, Issue 5 , Pages 773-799, May 2010

KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD–Mineral and Bone Disorder (CKD-MBD)

  • Katrin Uhlig, MD, MS

      Affiliations

    • Tufts Medical Center, Tufts University School of Medicine, Boston MA
    • Corresponding Author InformationAddress correspondence to Katrin Uhlig, MD, MS, Tufts Medical Center, Box 391, 800 Washington St, Boston MA 02445
  • ,
  • Jeffrey S. Berns, MD

      Affiliations

    • University of Pennsylvania School of Medicine, Philadelphia, PA
  • ,
  • Bryan Kestenbaum, MD, MS

      Affiliations

    • University of Washington Kidney Research Institute, Seattle, WA
  • ,
  • Raj Kumar, MBBS

      Affiliations

    • Mayo Clinic College of Medicine, Rochester, MN
  • ,
  • Mary B. Leonard, MD

      Affiliations

    • The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA
  • ,
  • Kevin J. Martin, MB, BCh

      Affiliations

    • Division of Nephrology, Saint Louis University, St. Louis, MO
  • ,
  • Stuart M. Sprague, DO

      Affiliations

    • North Shore University Health System University of Chicago Pritzker School of Medicine, Chicago, IL
  • ,
  • Stanley Goldfarb, MD

      Affiliations

    • University of Pennsylvania School of Medicine, Philadelphia, PA

published online 05 April 2010.

This commentary provides a US perspective on the 2009 KDIGO (Kidney Disease: Improving Global Outcomes) Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD–MBD). KDIGO is an independent international organization with the primary mission of the promotion, coordination, collaboration, and integration of initiatives to develop and implement clinical practice guidelines for the care of patients with kidney disease. The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI), recognizing that international guidelines need to be adapted for each country, convened a group of experts to comment on the application and implementation of the KDIGO guideline for patients with CKD in the United States. This commentary puts the KDIGO guideline into the context of the supporting evidence and the setting of care delivered in the United States and summarizes important differences between prior KDOQI guidelines and the newer KDIGO guideline. It also considers the potential impact of a new bundled payment system for dialysis clinics.

The KDIGO guideline addresses the evaluation and treatment of abnormalities of CKD-MBD in adults and children with CKD stages 3-5 on long-term dialysis therapy or with a kidney transplant. Tests considered are those that relate to laboratory, bone, and cardiovascular abnormality detection and monitoring. Treatments considered are interventions to treat hyperphosphatemia, hyperparathyroidism, and bone disease in patients with CKD stages 3-5D and 1-5T. Limitations of the evidence are discussed. The lack of definitive clinical outcome trials explains why most recommendations are not of level 1 but of level 2 strength, which means weak or discretionary recommendations. Suggestions for future research highlight priority areas.

Index Words: Clinical practice guideline, guideline adaptation, chronic kidney disease, mineral and bone disease, renal osteodystrophy, Kidney Disease Outcomes Quality Initiative (KDOQI), Kidney Disease: Improving Global Outcomes (KDIGO)

 

 Originally published online as doi:10.1053/j.ajkd.2010.02.340 on April 5, 2010.

 Reprint requests to Kerry Willis, PhD, National Kidney Foundation, 30 E 33rd St, New York, NY 10016. E-mail: kerryw@kidney.org

PII: S0272-6386(10)00489-0

doi:10.1053/j.ajkd.2010.02.340

American Journal of Kidney Diseases
Volume 55, Issue 5 , Pages 773-799, May 2010